AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2022012 — intervention group
Group type: COMPARATOR
Intervention: Argatroban (1 micrograms/kg/min) alone
Number of subjects: 6
Study 6177374 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified human leucocyte interferon administered by repeated nasal sprays
Number of subjects: 0
Study 6177374 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study 31064371 — intervention group
Group type: EXPERIMENTAL
Intervention: Job Management Program (JUMP)
Number of subjects: 0
Study 31064371 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 0
Study 29305890 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training program consisting of six training sessions with cognitive tasks aimed at enhancing inhibition towards unhealthy food items and decreasing food approach and attentional biases
Number of subjects: 36
Study 29305890 — intervention group
Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 36
Study 26880285 — intervention group
Group type: EXPERIMENTAL
Intervention: Appearance comparison instruction
Number of subjects: 246
Study 26880285 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer norms instruction
Number of subjects: 246
Study 26880285 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 246
Study 24954556 — intervention group
Group type: EXPERIMENTAL
Intervention: Overshadowing by salient tasting beverages (OS+)
Number of subjects: 24
Study 24954556 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (familiar beverage, water; OS-)
Number of subjects: 24
Study 22446097 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 0
Study 19096921 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone plus structured parent training
Number of subjects: 0
Study 19096921 — intervention group
Group type: COMPARATOR
Intervention: Risperidone only
Number of subjects: 0
Study 17585213 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 224
Study 17585213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 224
Study 16167250 — intervention group
Group type: EXPERIMENTAL
Intervention: Hereditary nonpolyposis colorectal cancer (HNPCC) patients
Number of subjects: 167
Study 11914996 — intervention group
Group type: EXPERIMENTAL
Intervention: ertapenem
Number of subjects: 502
Study 11914996 — intervention group
Group type: COMPARATOR
Intervention: ceftriaxone
Number of subjects: 502
Study 11424510 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly iron supplementation (200 mg ferrous fumarate and 200 mg folic acid) for 24 weeks
Number of subjects: 280
Study 11424510 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo)
Number of subjects: 280
Study 9764453 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser ablation
Number of subjects: 31
Study 9764453 — intervention group
Group type: COMPARATOR
Intervention: Transurethral electrovaporization (TVP)
Number of subjects: 31
Study 7828249 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial hyperoxia (PaO2 > 200 mmHg) at PaCO2 of 25 mmHg
Number of subjects: 12
Study 7828249 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial hyperoxia (PaO2 > 200 mmHg) at PaCO2 of 30 mmHg
Number of subjects: 12
Study 3134786 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 49
Study 3134786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 7828347 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate administered every 14 days (60 mg/dose)
Number of subjects: 34
Study 7828347 — intervention group
Group type: COMPARATOR
Intervention: Pamidronate administered every 21 days (60 mg/dose)
Number of subjects: 34
Study 355033 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinic acid compound
Number of subjects: 27
Study 355033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 31397487 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-month ticagrelor monotherapy following 1-month dual antiplatelet therapy (DAPT)
Number of subjects: 4570
Study 31397487 — intervention group
Group type: COMPARATOR
Intervention: 12-month aspirin monotherapy following 12-month DAPT
Number of subjects: 4570
Study 30597946 — intervention group
Group type: EXPERIMENTAL
Intervention: Martial arts based psycho-social intervention
Number of subjects: 283
Study 30597946 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 283
Study 26285023 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg · kg(‐1) body mass TYR
Number of subjects: 21
Study 26285023 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg · kg(‐1) body mass TYR
Number of subjects: 21
Study 26285023 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sugar-free drink)
Number of subjects: 21
Study 24472321 — intervention group
Group type: EXPERIMENTAL
Intervention: Four isocaloric eating episodes at T0, T60, T120, and T180min (F4)
Number of subjects: 17
Study 24472321 — intervention group
Group type: COMPARATOR
Intervention: One eating episode at T0 (F1)
Number of subjects: 17
Study 22281448 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 50
Study 22281448 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Sleep Intervention (BSI)
Number of subjects: 50
Study 22281448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 19878043 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluroshield (sealant with fluoride)
Number of subjects: 10
Study 19878043 — intervention group
Group type: EXPERIMENTAL
Intervention: Aegis (sealant with ACP)
Number of subjects: 10
Study 19878043 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental sealant with fluoride (ESF)
Number of subjects: 10
Study 19878043 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental sealant with fluoride/ACP (ACP-F)
Number of subjects: 10
Study 19878043 — intervention group
Group type: COMPARATOR
Intervention: Control group (demineralized enamel slab)
Number of subjects: 10
Study 17510766 — intervention group
Group type: EXPERIMENTAL
Intervention: Kugel procedure
Number of subjects: 172
Study 17510766 — intervention group
Group type: COMPARATOR
Intervention: Lichtenstein procedure
Number of subjects: 172
Study 16319785 — intervention group
Group type: EXPERIMENTAL
Intervention: Iyengar yoga classes (2 weekly 90-min sessions for 3 months)
Number of subjects: 24
Study 16319785 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 24
Study 12395330 — intervention group
Group type: EXPERIMENTAL
Intervention: VPA-985 300 mg
Number of subjects: 25
Study 12395330 — intervention group
Group type: EXPERIMENTAL
Intervention: VPA-985 (doses 100 mg or greater)
Number of subjects: 25
Study 12395330 — intervention group
Group type: EXPERIMENTAL
Intervention: VPA-985
Number of subjects: 25
Study 12395330 — intervention group
Group type: EXPERIMENTAL
Intervention: VPA-985 (100 mg to 200 mg)
Number of subjects: 25
Study 12395330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 10091762 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-intense arm: cisplatin 35 mg/m2 and etoposide 200 mg/m2 on Days 1-3 every 4 weeks.
Number of subjects: 123
Study 10091762 — intervention group
Group type: COMPARATOR
Intervention: Dose-dense arm: same chemotherapy schedule every 3 weeks plus 5 microg/kg of rhGM-CSF on Days 4-13.
Number of subjects: 123
Study 10091762 — intervention group
Group type: COMPARATOR
Intervention: Dose-dense arm
Number of subjects: 123
Study 10091762 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-intense arm
Number of subjects: 123
Study 7584517 — intervention group
Group type: EXPERIMENTAL
Intervention: Gas mixture with reduced oxygen content (H; FIO2: 0.14)
Number of subjects: 15
Study 7584517 — intervention group
Group type: COMPARATOR
Intervention: Normal air (N)
Number of subjects: 15
Study 2247670 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratracheal cocaine (4 ml, 2.5%)
Number of subjects: 60
Study 2247670 — intervention group
Group type: COMPARATOR
Intervention: Intratracheal lignocaine (4 ml, 4%)
Number of subjects: 60
Study 7392404 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term intensive physical training according to a special program (Group 2)
Number of subjects: 53
Study 7392404 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 1)
Number of subjects: 53
Study 30332674 — intervention group
Group type: EXPERIMENTAL
Intervention: 577-nm multispot laser with a 20-ms pulse duration
Number of subjects: 41
Study 30332674 — intervention group
Group type: COMPARATOR
Intervention: 532-nm single-spot laser with a 100-ms pulse duration
Number of subjects: 41
Study 29267506 — intervention group
Group type: EXPERIMENTAL
Intervention: Arndt-endobronchial blocker plus laryngeal mask airway (LMA)
Number of subjects: 80
Study 29267506 — intervention group
Group type: COMPARATOR
Intervention: Left-sided double-lumen endobronchial tube (L-DLT)
Number of subjects: 80
Study 25730811 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1mg/kg (Group III)
Number of subjects: 400
Study 25730811 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 1.5mg/kg (Group IV)
Number of subjects: 400
Study 25730811 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride, Group I)
Number of subjects: 400
Study 25730811 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 0.5mg/kg (Group II)
Number of subjects: 400
Study 23855898 — intervention group
Group type: EXPERIMENTAL
Intervention: Baska mask
Number of subjects: 150
Study 23855898 — intervention group
Group type: COMPARATOR
Intervention: cLMA
Number of subjects: 150
Study 21550218 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa powder with 500 mL of skimmed milk/day (C + M)
Number of subjects: 42
Study 21550218 — intervention group
Group type: COMPARATOR
Intervention: Only 500 mL/day of skimmed milk (M)
Number of subjects: 42
Study 19698903 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive quetiapine with lithium or valproate
Number of subjects: 0
Study 19698903 — intervention group
Group type: COMPARATOR
Intervention: Placebo + lithium/valproate
Number of subjects: 0
Study 17450257 — intervention group
Group type: EXPERIMENTAL
Intervention: CYFRA 21-1 assay (immunoradiometric assay)
Number of subjects: 96
Study 15226463 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low-fat diet (VLF, 12% energy from fat)
Number of subjects: 62
Study 15226463 — intervention group
Group type: COMPARATOR
Intervention: High monounsaturated fat diet (HIMO, 35% energy from fat)
Number of subjects: 62
Study 15226463 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low-fat diet (VLF)
Number of subjects: 62
Study 15226463 — intervention group
Group type: COMPARATOR
Intervention: High monounsaturated fat diet (HIMO)
Number of subjects: 62
Study 11860401 — intervention group
Group type: EXPERIMENTAL
Intervention: Single subject trial
Number of subjects: 0
Study 10221740 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug therapy
Number of subjects: 0
Study 10221740 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8619572 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimantadine 100 mg/day
Number of subjects: 328
Study 8619572 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimantadine 200 mg/day
Number of subjects: 328
Study 8619572 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Rimantadine (100 mg/day and 200 mg/day)
Number of subjects: 328
Study 8619572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 328
Study 2153185 — intervention group
Group type: EXPERIMENTAL
Intervention: CRB 87 (10(6.6)‐10(7.6) TCID50)
Number of subjects: 29
Study 2153185 — intervention group
Group type: EXPERIMENTAL
Intervention: CRB 87 (10(7.6) TCID50)
Number of subjects: 29
Study 2153185 — intervention group
Group type: COMPARATOR
Intervention: Wild-type influenza B/Texas/1/84 (10(3.9)‐10(7.1) TCID50)
Number of subjects: 29
Study 2153185 — intervention group
Group type: COMPARATOR
Intervention: Wild-type virus (10(7.1) TCID50)
Number of subjects: 29
Study 320918 — intervention group
Group type: EXPERIMENTAL
Intervention: Food extract injection therapy
Number of subjects: 0
Study 320918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29321031 — intervention group
Group type: EXPERIMENTAL
Intervention: Deprescribing preventive cardiovascular medication (intervention group)
Number of subjects: 1067
Study 29321031 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1067
Study 26978860 — intervention group
Group type: EXPERIMENTAL
Intervention: DAMA+SOC
Number of subjects: 29
Study 26978860 — intervention group
Group type: COMPARATOR
Intervention: SOC alone
Number of subjects: 29
Study 24619957 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-hour self-directed workbook intervention
Number of subjects: 41
Study 24619957 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 41
Study 21925957 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine-125 (125I) monotherapy to a prescribed dose of 144Gy
Number of subjects: 1466
Study 21925957 — intervention group
Group type: EXPERIMENTAL
Intervention: D(90) > 140Gy compared with lower doses
Number of subjects: 1466
Study 21925957 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant and concurrent androgen deprivation therapy
Number of subjects: 1466
Study 20444631 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial-based interventions
Number of subjects: 0
Study 20444631 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported disability measures
Number of subjects: 0
Study 20444631 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessed psychological outcomes
Number of subjects: 0
Study 17275225 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal product containing 72 mg/dose of isoflavones (BIO)
Number of subjects: 125
Study 17275225 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 16138529 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Involvement in Care (FIC) protocol
Number of subjects: 164
Study 16138529 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 164
Study 12005117 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium lauryl sulphate (SLS)
Number of subjects: 12
Study 12005117 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonanoic acid (NON)
Number of subjects: 12
Study 12005117 — intervention group
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (RA)
Number of subjects: 12
Study 12005117 — intervention group
Group type: COMPARATOR
Intervention: Vehicle treatment
Number of subjects: 12
Study 9527293 — intervention group
Group type: EXPERIMENTAL
Intervention: GP diagnostics
Number of subjects: 1838
Study 9527293 — intervention group
Group type: COMPARATOR
Intervention: Sentinel Stations criteria
Number of subjects: 1838
Study 9527293 — intervention group
Group type: COMPARATOR
Intervention: ICHPPC-2 criteria
Number of subjects: 1838
Study 9527293 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of symptoms (fever, coughing, acute onset)
Number of subjects: 1838
Study 8586319 — intervention group
Group type: EXPERIMENTAL
Intervention: UF heparin, 10,000 IU s.c., b.d.
Number of subjects: 66
Study 8586319 — intervention group
Group type: COMPARATOR
Intervention: Fragmin, 5,000 IU anti-factor Xa s.c., b.d.
Number of subjects: 66
Study 2093079 — intervention group
Group type: EXPERIMENTAL
Intervention: Alizapride
Number of subjects: 0
Study 2093079 — intervention group
Group type: COMPARATOR
Intervention: Alizapride + Dexamethasone
Number of subjects: 0
Study 359098 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose spinal irradiation (2400 rads) without intrathecal methotrexate
Number of subjects: 0
Study 359098 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 600 mg/m2 given intravenously every 12 weeks
Number of subjects: 0
Study 359098 — intervention group
Group type: EXPERIMENTAL
Intervention: Four 12-week courses of chemotherapy after eight courses (total duration two years)
Number of subjects: 0
Study 359098 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender comparison (Girls vs Boys)
Number of subjects: 0
Study 30852728 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention (WeTest) delivered via WeChat app; participants received two oral HIVST kits and access to a private WeChat group with app-based messages and referrals to health services.
Number of subjects: 100
Study 30852728 — intervention group
Group type: COMPARATOR
Intervention: Control group received two oral HIVST kits only.
Number of subjects: 100
Study 28044049 — intervention group
Group type: EXPERIMENTAL
Intervention: Wahakura
Number of subjects: 200
Study 28044049 — intervention group
Group type: COMPARATOR
Intervention: Bassinet
Number of subjects: 200
Study 25996255 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient decision support
Number of subjects: 400
Study 25996255 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 400
Study 24377211 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep puncture group (electroacupuncture at Tianshu ST 25, needle depth 20-65 mm)
Number of subjects: 128
Study 24377211 — intervention group
Group type: COMPARATOR
Intervention: Western medication group (lactulose oral liquid)
Number of subjects: 128
Study 24377211 — intervention group
Group type: COMPARATOR
Intervention: Shallow puncture group (electroacupuncture at Tianshu ST 25, needle depth 5-8 mm)
Number of subjects: 128
Study 21281407 — intervention group
Group type: EXPERIMENTAL
Intervention: co-trimoxazole (cotox)
Number of subjects: 600
Study 21281407 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 600
Study 19433666 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba 120 mg twice a day
Number of subjects: 3069
Study 19433666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3069
Study 16144819 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (50% reduction of overweight/15% absolute weight loss, using a very low-calorie diet)
Number of subjects: 11
Study 14613263 — intervention group
Group type: EXPERIMENTAL
Intervention: Data-driven outcomes
Number of subjects: 264
Study 14613263 — intervention group
Group type: EXPERIMENTAL
Intervention: DMARDs
Number of subjects: 264
Study 14613263 — intervention group
Group type: COMPARATOR
Intervention: Coxib versus placebo
Number of subjects: 264
Study 14613263 — intervention group
Group type: EXPERIMENTAL
Intervention: ACR20
Number of subjects: 264
Study 14613263 — intervention group
Group type: EXPERIMENTAL
Intervention: DDAS
Number of subjects: 264
Study 11007567 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB (3 g/day)
Number of subjects: 13
Study 11007567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 9173422 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (50 micrograms b.i.d. by MDI)
Number of subjects: 16
Study 9173422 — intervention group
Group type: COMPARATOR
Intervention: Theophylline (Uniphyllin; 600 mg nocte orally)
Number of subjects: 16
Study 9173422 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 16
Study 9173422 — intervention group
Group type: COMPARATOR
Intervention: Theophylline
Number of subjects: 16
Study 7877825 — intervention group
Group type: EXPERIMENTAL
Intervention: 131I-HIPDM
Number of subjects: 0
Study 3362554 — intervention group
Group type: EXPERIMENTAL
Intervention: Orally administered ethyl alcohol (1 ml/kg of 100% ethyl alcohol + 1 ml/kg tonic water)
Number of subjects: 18
Study 3362554 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.17 mg/kg s.q. morphine
Number of subjects: 18
Study 3362554 — intervention group
Group type: COMPARATOR
Intervention: Pharmacologically active placebo (atropine)
Number of subjects: 18
Study 3362554 — intervention group
Group type: COMPARATOR
Intervention: Totally inactive placebo (saline)
Number of subjects: 18
Study 30298371 — intervention group
Group type: EXPERIMENTAL
Intervention: Method A (IQ-SPECT)
Number of subjects: 55
Study 29038157 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased plasma ferritin concentration (doubling)
Number of subjects: 62537
Study 29038157 — intervention group
Group type: EXPERIMENTAL
Intervention: C282Y/C282Y genotype
Number of subjects: 62537
Study 24476530 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation intervention involving a dedicated Generic Rehabilitation Assistant (GRA) trained in physiotherapy, dietetics, occupational therapy, and speech/language therapy, from ICU discharge to 3 months post-discharge.
Number of subjects: 0
Study 24476530 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 22575311 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraprocedural thrombotic events (IPTE)
Number of subjects: 3428
Study 20739378 — intervention group
Group type: EXPERIMENTAL
Intervention: Piragliatin 25 mg
Number of subjects: 15
Study 20739378 — intervention group
Group type: EXPERIMENTAL
Intervention: Piragliatin 100 mg
Number of subjects: 15
Study 20739378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 18999909 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza mailing intervention
Number of subjects: 134791
Study 18999909 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse advice service mailing intervention
Number of subjects: 134791
Study 18999909 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 134791
Study 15695785 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucking lemon candy started within 1 hour after radioiodine ingestion (group A)
Number of subjects: 230
Study 15695785 — intervention group
Group type: COMPARATOR
Intervention: Sucking lemon candy withheld until 24 hours after radioiodine ingestion (group B)
Number of subjects: 230
Study 14669165 — intervention group
Group type: EXPERIMENTAL
Intervention: Low adiponectin levels
Number of subjects: 101
Study 14669165 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest tertile of adiponectin
Number of subjects: 101
Study 10767728 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 20-40 mg/day
Number of subjects: 336
Study 10767728 — intervention group
Group type: COMPARATOR
Intervention: Mianserin 30-60 mg/day
Number of subjects: 336
Study 10767728 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 336
Study 10767728 — intervention group
Group type: COMPARATOR
Intervention: Mianserin
Number of subjects: 336
Study 10767728 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram and Mianserin
Number of subjects: 336